The China Alliance for Type 1 Diabetes (CAT1D) is committed to exploring and implementing the model of graded diagnosis and treatment of type 1 diabetes and comprehensive management of outpatient service, carrying out a series of educational activities for patients, and cooperating in the development of multi-center prospective clinical research on type 1 diabetes.
1. Through the CAT1D, expand the cohort construction of type 1 diabetes patients and first-level relatives in China, establish the electronic information database of type 1 diabetes, and lay a foundation for obtaining the research data of type 1 diabetes in China. 2. observe and study the occurrence and development rules of acute and chronic complications of type 1 diabetes in China, analyze the influencing factors, and provide intervention means for reducing acute complications and preventing chronic complications. 3. Through the established management platform and structured education system, verify and promote the comprehensive management mode based on structured education, and build a standard treatment plan and process based on evidence-based science and suitable for Chinese people and medical background. 4. By using mobile health (mHealth) and Artificial Intelligence (AI) technologies, a new mode of intelligent structured education is established, which provides a new way to explore the individualized education management mode and improve the outcome of chronic diseases through modern technology.
Study Type
OBSERVATIONAL
Enrollment
500
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
Changsha, Hunan, China
RECRUITINGchanges in serum hemoglobin A1c level
A1c reflects the average blood glucose level in the past 3 months.
Time frame: Baseline and every up to 12 weeks afterwards
changes in Time in range (TIR)
TIR measures the time where the blood glucose remains within the proposed target range.
Time frame: Baseline and every up to 12 weeks afterwards
C-peptide
C-peptide are measured before and 2-hour after a mixed meal tolerance test at each follow-up of this study
Time frame: Baseline and every up to 12 weeks afterwards
Change in titer of autoantibodies
Time frame: Baseline and every up to 12 weeks afterwards
Fasting blood glucose
the blood sugar level after fasting for eight hours
Time frame: Baseline and every up to 12 weeks afterwards
Systolic blood pressure
Systolic blood pressure
Time frame: Baseline and every up to 12 weeks afterwards
Diastolic blood pressure
Diastolic blood pressure
Time frame: Baseline and every up to 12 weeks afterwards
Change in lipid profiles
Including triglyceride, total cholesterol, HDL-cholesterol and LDL-cholesterol
Time frame: Baseline and every up to 12 weeks afterwards
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Height in meters
Height in meters will be measured
Time frame: Baseline and every up to 12 weeks afterwards
Weight in kilograms
Weight in kilograms will be measured
Time frame: Baseline and every every up to 12 weeks afterwards
Stool samples
Time frame: Baseline and every up to 12 weeks afterwards
Adverse effects
Adverse effects are recorded at each time-point of the follow-up
Time frame: Baseline and every up to 12 weeks afterwards